Imugene says its HER2 vaccine hit the mark in a phase 1b trial, setting up a phase 2 study that will start recruiting patients in the new year.

The agreement sees Innovent pay $40 million upfront and commit to about $350 million in milestones for a trio of drugs that are in phase 2 and 3.

The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline.

Idera touts higher response rate from the combo than Yervoy alone and a 76.5% disease control rate.

Gilead swipes Roche pharma chief for CEO post; Merck promotes oncology, vaccine executives; and Gritstone names new antibody therapeutics chief.

Bellicum has the first data on BPX-601, a CAR-T with a built-in activation switch to boost its effects, and says it shows signs of biologic activity.

In this week's EuroBiotech Report, AC Immune lands Lilly deal, AstraZeneca’s tremelimumab fails again and Novo inks diabetes deal.

In our EuroBiotech roundup this week, Affimed eyes accelerated approval, Evox gets Gates funding and ex-Rigontec CEO lands new gig.

The trial found the histamine type 4 receptor antagonist had no effect on vigilance and cognitive performance.

The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.